EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent
EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent
On April 16, 2024, the United States Patent and Trademark Office issued patent number 11957664 to Adial Pharmaceuticals Inc (NASDAQ:ADIL).
2024年4月16日，美国专利商标局向阿迪尔制药公司（纳斯达克股票代码：ADIL）颁发了专利号为11957664的专利。
This patent expands Adial's intellectual property protection and covers the combination of the company's proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and other drug dependencies, such as opioid use disorder (OUD), with the company's lead investigational new drug product AD04.
该专利扩大了Adial的知识产权保护，涵盖了该公司专有的基因诊断与该公司主要研究新药产品AD04相结合，该诊断旨在识别具有特定基因型的患者，用于酒精使用障碍（AUD）和其他药物依赖的基因靶向治疗，例如阿片类药物使用障碍（OUD）。
Related: EXCLUSIVE: Adial Pharmaceuticals Announces New US Patent Covering Its Molecular Genetic Diagnosing For Alcohol, Drug Dependence.
相关： 独家：Adial Pharmicals宣布新的美国专利，涵盖其酒精和药物依赖的分子遗传学诊断。
Cary Claiborne, CEO of Adial, commented, "We are proud to have secured this new patent, which covers important aspects of the combination of our proprietary genetic diagnostic and AD04 to treat AUD, OUD, and other drug dependencies."
Adial首席执行官Cary Claiborne评论说：“我们很自豪能够获得这项新专利，该专利涵盖了我们专有的基因诊断与AD04相结合以治疗AUD、OUD和其他药物依赖的重要方面。”
"Importantly, we have identified specific genotypes that responded with clinically meaningful changes in drinking behavior compared to placebo in the AD04 post hoc analysis, representing an addressable market of approximately $40 billion in the U.S. alone," Claiborne added.
克莱伯恩补充说：“重要的是，在AD04事后分析中，与安慰剂相比，我们已经确定了特定的基因型，这些基因型的饮酒行为会发生具有临床意义的变化，仅在美国就有约400亿美元的潜在市场。”
In February, Adial Pharmaceuticals received a U.S. patent allowance covering AD04 and its ability to target the serotonin transporter gene for the potential treatment of opioid use disorder.
2月，Adial Pharmicals获得了一项美国专利许可，涵盖AD04及其靶向血清素转运体基因以潜在治疗阿片类药物使用障碍的能力。
Earlier this month, Adial Pharmaceuticals exclusively told Benzinga regarding the publication of a peer-reviewed article highlighting the clinical results, strong safety profile, and high compliance among patients administered AD04 (low-dose ondansetron).
本月早些时候，Adial Pharmicals独家表示 本辛加 关于发表一篇经过同行评审的文章，该文章重点介绍了服用AD04（低剂量恩丹西酮）的患者的临床结果、良好的安全性和高依从性。
The publication also reported the results of a new study analyzing the liver safety profile of AD04 compared with placebo in subjects with AUD in the company's prior Phase 3 trial.
该出版物还报告了一项新研究的结果，该研究分析了该公司先前的3期试验中AD04与安慰剂对比的AUD受试者的肝脏安全性。
Price Action: ADIL shares closed at $1.93 on Friday.
价格走势：周五，ADIL股价收于1.93美元。